Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2021
   Trial
2. A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Infectious diseases and therapy · 2025
   Review
3. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025
   Review
4. Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy.BMC infectious diseases · 2024
   Article
5. Dalbavancin in clinical practice in Spain: a 2 year retrospective study.JAC-antimicrobial resistance · 2022
   Article
6. Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial.Infectious diseases and therapy · 2020
   Article
7. Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department.The American journal of emergency medicine · 2020
   Article
8. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.Antimicrobial agents and chemotherapy · 2018
   Article
9. Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.Journal of cardiothoracic surgery · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as